Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis

BACKGROUND: Given the increasing use of immune checkpoint inhibitors (ICIs), a concomitant rise in adverse events is inevitable. In a recent Phase III trial of ICIs versus placebo, we found the staggering difference of incidence of fatal adverse events (FAEs). Hence, we should determine the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yi, Zhang, Ning, Pang, Hailin, Gao, Xiaobo, Zhang, Helong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385768/
https://www.ncbi.nlm.nih.gov/pubmed/30858709
http://dx.doi.org/10.2147/TCRM.S191022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385768/
https://www.ncbi.nlm.nih.gov/pubmed/30858709
http://dx.doi.org/10.2147/TCRM.S191022

Ejemplares similares